Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome
The aim of this study is to compare the hormonal, metabolic and clinical effects of metformin and liraglutide in infertile women with PCOs.
|Condition or Disease
It is a Prospective randomized controlled trial .The study will include 80 randomly selected infertile women aged between 18 and 45 years, from Gynecology and obstetrics department Beni-Suef University Hospital whom diagnosed with polycystic ovarian syndrome (PCOS), The study will include two groups; each group consists of 40 patients:-
Group1 (n=40) will be treated by liraglutide monotherapy.
Group 2 (n=40) will be treated by metformin monotherapy.
Group 3 (n=40) will be a control group.
To assess the metabolic effect of each treatment, the following parameters will be assessed before and after the treatment
To assess the hormonal effect of each treatment, the following tests will be assessed before and after treatment
Total Testosterone (TT)
To assess the clinical effect of the drugs, the following will be assessed before and after treatment:
The number of medium size follicles and large size follicles and the endometrium thickness were assessed on the tenth or eleventh day of menstruation. The chemical and clinical pregnancy rates were evaluated
Arms and Interventions
Saxenda® starting dose is 0.6 mg per day for 1 week.1. Patients increase the dose by 0.6 mg each week until the full maintenance dose of 3 mg is reached
glucagon-like peptide 1 receptor agonist
|Active Comparator: metformin
the patient is given Glucophage 1000 mg tab once daily after lunch for 1month
|No Intervention: control
not given any drug
Primary Outcome Measures
- Body weight loss [1 months]
basal body weight - body weight reached after treatment
aged between 20 and 45 years
congenital adrenal hyperplasia
poorly controlled thyroid disease
Taking antidiabetic drugs which can affect insulin resistance
chronic kidney disease and history of recurrent urinary tract infections
documented use of oral hormonal contraceptives and hormone-releasing implants
Contacts and Locations
|Beni-suef university Hospital
Sponsors and Collaborators
- Beni-Suef University
- Study Director: Beni-Suef University, Clinical Pharmacy Faculty of Pharmacy Beni-Suef University
Study Documents (Full-Text)None provided.
- Liraglutide Polycystic Ovary